Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720291 | 0.90 | CTNNB1 (0.47) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL6743982 | 0.79 | CTNNB1 (0.51) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL6443038 | 0.78 | CTNNB1 (0.44) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL9678479 | 0.76 | TDP1 (0.53) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL10857564 | 0.76 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL9676538 | 0.76 | TDP1 (0.53) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL15096099 | 0.76 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL15096098 | 0.76 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL11567192 | 0.76 | CTNNB1 (0.45) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL197908 | 0.76 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-6008228-A | COMPRISING A MIXTURE OF CARRIER MONOGLYCERIDES OF MEDIUM CHAIN-FATTY ACIDS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| EP-0831826-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039142-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PROTEINASE INHIBITOR AND A MONOGLYCERIDE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-12 | — | — | WO | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0184550-B1 | 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| EP-0374097-A2 | Use of peptide isosteres as retroviral protease inhibitors | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| EP-0374098-A2 | Inhibitors of retroviral proteases | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| US-4931591-A | Novel 5-amino-4-hydroxyvaleryl derivatives | CIBA-GEIGY CORPORATION (US) | 1990-06-05 | — | — | US | disclosed |
| US-4727060-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0184550-A2 | 5-Amino-4-hydroxy valeryl amide derivatives | CIBA-GEIGY AG (CH) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CTNNB1 1728/4885TDP1 758/4885CYP1A2 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.